Biogen Details Case for Controversial Alzheimer’s Drug

  • 📰 WSJ
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 63%

United States Headlines News

United States Latest News,United States Headlines

Biotech company Biogen presents data for its experimental Alzheimer’s drug after terminating studies in March

Biogen Inc. on Thursday tried to make the case for why two aborted studies of its experimental Alzheimer’s disease drug support its plan to seek approval from U.S. regulators, but skeptics said they remained unconvinced that the drug is effective.

Biogen presented additional details from the studies at the Clinical Trials on Alzheimer’s Disease conference in San Diego, and said the new data showed that patients receiving the highest dose of the drug appeared to have slower declines in their cognitive abilities than patients...

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Well, can they explain bioengineering of whipped cream in their snakes at winsteads in KCMO or genetically engineered cereals and dairy products from Quiktrip and Sunfresh in the Westport area. It's disgusting to even think that these foods are made with human breast milk.

The data doesn't support it.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 98. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

New Biogen data showed no major safety issues for its Alzheimer's drugBiogen Inc on Thursday presented new data on its experimental Alzheimer's d... It investigated itself and found no issues. It has to be fine. Just like Boeing!
Source: Reuters - 🏆 2. / 97 Read more »

Biogen's stock rises 4% after releasing new data on late-stage Alzheimer's drugAnalysts who parsed through it, said the lack of any new negatives in the report means that they expect the company will take the data to the Food and Drug Administration. I predict in 10-20 years from now, we weill look upon this moment and realized they faked their data. They knew it wouldn’t work, but wanted to recouo losses. You heard it here first.
Source: CNBC - 🏆 12. / 72 Read more »

New Biogen data showed no major safety issues for its Alzheimer's drugBiogen Inc on Thursday presented new data on its experimental Alzheimer's d... It investigated itself and found no issues. It has to be fine. Just like Boeing!
Source: Reuters - 🏆 2. / 97 Read more »

New details emerge on drug that may slow Alzheimer’s diseaseExcitement and skepticism have surrounded the drug since its developers stopped studies earlier this year because it didn't seem to be working. I will need that drug as well.
Source: NBCNews - 🏆 10. / 86 Read more »

Drug curbs delusions, eases anger in Alzheimer's patients, researchers findIf regulators approve it, the drug could become the first new medicine for Alzheimer's patients in nearly two decades. wow, my grandma died of alzheimers. it's great to see the steps they've taken in recent years to find a cure. I know were a long way off, but itz always uplifting to see articles like this. navgirl63 Can we start putting this in Trump's Happy Meals? Now for a President BernieSanders and MedicareForAll to make this affordable for all. Medicare Fro All will have a $250 annual max cap on prescriptions.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

Drug can curb dementia’s delusions, researchers findSAN DIEGO (AP) — A drug that curbs delusions in Parkinson's patients did the same for people with Alzheimer's disease and other forms of dementia in a study that was stopped early because the... Can we get some for Trump stat ? Does it work on Trump Republicans? Can we spike Trump's hamberders with it?
Source: AP - 🏆 728. / 51 Read more »